Renowned doctor calls it a “Plandemic in the works.”
- Mayo Clinic Laboratories is preparing to carry out “10,000” Monkeypox tests per week, according to a Monday publication in the medical research website Healio, even though there have only been 866 infections in the U.S.
- “Mayo Clinic Laboratories will accept specimens from anywhere in the country and is expected to perform up to 10,000 [Monkeypox] tests per week,” the publication reads.
- The Mayo Clinic is now the second commercial laboratory in the U.S. to begin monkeypox testing, as Labcorp began testing last week. But Mayo Clinic is only “one of five” commercial laboratories that will receive orthopoxvirus tests from the U.S. Health and Human Services (HHS), the Healio publication explains. In fact, the U.S. Centers for Disease Control and Prevention (CDC) expects “additional laboratories named by HHS—Aegis Science, Quest Diagnostics and Sonic Healthcare—to begin testing later this summer as the monkeypox outbreak continues.”
- However, the CDC reports that there have only been 866 total confirmed monkeypox/orthopoxvirus cases in the U.S. as of Monday, raising questions about the size of the mainstream medical community’s response to the problem.
- Dr. Richard Bartlett, a former appointee to then-Texas Gov. Rick Perry’s Health Disparities Task Force, told American Faith that he believes the Mayo Clinic’s extreme reaction makes it appear a “Plandemic is in the works” and pointed to the fact that the Biden administration had purchased 13 million doses of Monkeypox vaccine after the very first U.S. infection was confirmed in Massachusetts.
- Bartlett also called out problems with the new Monkeypox vaccine, revealing that he had “found no long-term safety data for this new Monkey poke for Monkeypox.” “What could go wrong? How many will cut in line out of fear for a shot without informed consent of the risk and benefits of the shot?” Dr. Bartlett asked.
MONKEYPOX CASES BY STATE:
|District Of Columbia||69|
- HHS awarded vaccine manufacturer Bavarian Nordic a $539 million contract for a smallpox vaccine in September 2017.
- Bavarian Nordic’s “Jynneos” vaccine—the first vaccine designed to prevent smallpox and monkeypox disease in adults who are considered at high risk of the viruses—was approved by the Food and Drug Administration (FDA) in September 2019, according to a Reuters report emphasizing the “risk” that Monkeypox “could be used as a weapon of biological warfare.” “Although naturally occurring smallpox disease is no longer a global threat, the intentional release of this highly contagious virus could have a devastating effect,” said the director of the FDA’s center for biologics evaluation and research, Peter Marks.
- Cardiac adverse events—already linked to COVID-19 vaccines—are warned to be of “special interest” on the Jynneos vaccine package insert. Cardiac adverse events of special interest (AESIs) were reported in “1.3%” of “smallpox vaccine-naïve” Jynneos recipients and “2.1%” of “smallpox vaccine-experienced” Jynneos recipients. Tromethamine, a drug used to treat heart attacks, is an ingredient in the Jynneos vaccine. The Jynneos package insert also warns, “The risk for a severe allergic reaction should be weighed against the risk for disease due to smallpox or monkeypox.”
- Dr. Anthony Fauci’s National Institutes of Health (NIH) funded research into Monkeypox treatments shortly before the virus began spreading worldwide. The grant summary argued, “The similarity between monkeypox and the variola virus, coupled with concerns about the potential of the variola virus as a potential bioterrorism agent, have placed monkeypox treatments at the forefront of public health and scientific research agendas in many countries.”
- The Biden administration announced last week that it would make another 144,000 doses of Bavarian Nordic’s Jynneos monkeypox vaccine available, after having already ordered 2.5 million doses at the beginning of the month. “Deliveries from this latest order will begin arriving at the SNS later this year and will continue through early 2023,” according to HHS. “Altogether, HHS anticipates making approximately 1.9 million doses of JYNNEOS available in 2022, with an additional 2.2 million available during the first half of 2023.”
- More than 99% of Monkeypox patients identify as “gay” or similar, according to the U.K. Health Security Agency.